Summary: Varian, a Siemens Healthineers company, received FDA 510(k) clearance for its IntelliBlate microwave ablation system, designed for soft tissue ablation. IntelliBlate offers greater predictability, precision, and control during procedures, utilizing single or dual probes with advanced features.
Key Takeaways:
- FDA Clearance: Varian’s IntelliBlate microwave ablation system received FDA 510(k) clearance for soft tissue ablation.
- Enhanced Precision and Control: The system features large, controlled spherical ablation zones, single or dual probes, and advanced features like Laser Disk Alignment and LED indicators for precise treatment.
- Versatility and Integration: IntelliBlate offers modular elements for expanded treatment capabilities and aims to integrate intelligent therapeutic technologies and image-guided innovations for comprehensive cancer care.
Varian, a Siemens Healthineers company, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its IntelliBlate microwave ablation system, intended for ablation of soft tissue. It is designed to provide clinicians with greater predictability, precision, and control during their procedures through microwave ablation.
Features and Capabilities
IntelliBlate produces large, controlled spherical ablation zones for predictable treatment delivery. With the option to utilize a single or dual probes—each with linked or independent controls—IntelliBlate delivers the versatility to meet the unique clinical needs of each patient. Precision and control are amplified by the Ximitry probe, which enables innovative features such as Laser Disk Alignment and intuitive LED indicators.
Modular and Flexible Design
Modular elements provide the flexibility for clinicians to expand their treatment capabilities to meet changing clinical demands, while keeping control over operational efficiency throughout the ablation procedure.
“IntelliBlate combines the features our customers say are most important for an efficient, integrated solution to seek improved levels of performance in microwave ablation,” says Dr. David Hahn, vice president and chief medical officer, Varian Interventional Solutions. “This innovative system brings new versatility in treatment options, fueling clinician-driven innovation to tackle a wide variety of cases. Real-time monitoring and treatment information at the tissue level aim to further empower care teams with the confidence to deliver highly personalized care to patients.”
Collaborative Development and Future Plans
The ability of IntelliBlate to act as a comprehensive microwave ablation ecosystem is the result of deep collaboration between Varian and clinical experts during the design and development process. With future plans to connect intelligent therapeutic technologies and image-guided innovations in a single platform, IntelliBlate aims to provide clinicians with greater predictability of probe placement, treatment delivery, and procedural confirmation.
Ablation techniques—including microwave ablation—represent minimally invasive alternatives to surgery. Microwave ablation achieves its results by delivering focused energy to localized disease sites to destroy soft tissue, and is an increasingly important part of a comprehensive portfolio of cancer care options.
